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ascular comorbidities and compli-
cations are the major causes of ex-
cessive mortality and costs in
patients with diabetes (1,2). For more
than half a century, overwhelming evi-
dence has been accumulating that dem-
onstrates signiﬁcant harmful effects of
hyperglycemia. As shown in the Multiple
Risk Factor Intervention Trial (MRFIT)
study, at any given level of major cardio-
vascularriskfactors,diabetesisassociated
with an odds ratio of 2–4 for cardiovas-
cular mortality, in comparison with sub-
jects without diabetes (3).
In a recently published 18-year fol-
low-up study on the impact of type 1 and
type 2 diabetes on cardiovascular mortal-
ity in middle-aged subjects from Finland,
theadjustedhazardratioforpatientswith
type1diabetesversusnodiabeteswas3.6
in men and 13.3 in women (4). The cor-
respondinghazardratiosfortype2diabe-
tes were 3.3 and 10.1, respectively. This
study conﬁrms harmful effects of hyper-
glycemia shown in high-level controlled
trials, such as the Diabetes Control and
Complications Trial (DCCT) for type 1
diabetes (5) and the U.K. Prospective Di-
abetes Study (UKPDS) for type 2 diabetes
(6). For 25 years, the Joslin Clinic con-
ducted the Diabetes Natural History
Study that followed up diabetic patients
diagnosed between 1939 and 1959. The
lifetime was 5 years less for men and 12
years less for women than for those in the
general population (7). A unique 29-year
complete follow-up study was conducted
on 166 patients (mean age 63 years) with
newly diagnosed type 2 diabetes. These
subjects were from a district outpatient
department in East Germany. The study
revealed a reduction in life expectancy by
5.3 and 6.4 years in men and women,
respectively (8).
Thus,today,immenseevidenceexists
on long-term follow-up, population-
based studies in patients with types 1 and
2 diabetes. This evidence convincingly
suggests that hyperglycemia or diabetes
itself is a key risk factor not only for dia-
betes-relateddiseases,butalsoforcardio-
vascularandall-causemortality.Basedon
their long-term population observational
study, Juutilainen et al. (4) calculated an
increment of cardiovascular mortality per
increase of 1 unit (%) A1C of 52.5% in
type 1 diabetes and of 7.5% in type 2 di-
abetes, respectively.
Recently, an interim analysis of the
Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study indicated that
aggressive reduction of A1C to 6.4% in
elderly patients with long-term type 2 di-
abetesandabaselinelevelofA1Cof8.1%
was associated with a 22% higher mortal-
ity rate compared with the standard care
group with a level of 7.5% A1C (9).
Therefore, the intensiﬁed polypharmacy
treatment of hyperglycemia was stopped
prematurely and a treatment target of
A1C between 7.0 and 7.9% was recom-
mended. This surprising outcome of in-
tensiﬁed treatment of hyperglycemia
could not be conﬁrmed in the Action in
Diabetes and Vascular Disease: Preterax
and Diamicron Modiﬁed Release Con-
trolled Evaluation (ADVANCE) study,
another large prospective trial for im-
proved diabetes control in patients with
type 2 diabetes, which showed a 10% rel-
ative reduction in the combined outcome
ofmicro-andmacrovasculareventsinthe
group with more intensive A1C control
(A1C 6.5%) compared with the standard
control group (A1C 7.3%) (10). At the
same time, the 13.3-year follow-up data
of the Danish multifactorial intervention
study in type 2 diabetes (STENO-2) were
published on 160 patients randomly as-
signed to receive either intensive or con-
ventional multimodal therapy with tight
glucose control, use of renin-angiotensin
system blockers, aspirin, and lipid-
lowering agents (11). At the end of the
intervention after 7.8 years, A1C was
7.9% for intensive therapy and 9% for
conventional therapy. At the end of fol-
low-up, A1C was 7.7 and 8.0%, respec-
tively (difference not signiﬁcant). Only a
minority of patients reached the target
A1C of 6.5% (after 7.8 years, 16 vs. 4%,
andafter13.3years,18vs.11%forinten-
siﬁed versus standard treatment, respec-
tively). By contrast, the majority of
intensiﬁed treated patients reached tar-
getsofbloodpressureandcholesterollev-
els. During the follow-up, 40 patients
died in the standard treatment group ver-
sus24(30%)intheinterventionarm(P
0.02). Diabetes-related microvascular
diseases were also impressively reduced.
By extrapolation of ACCORD interim re-
sults, and the convincing outcomes of
better treatment of blood pressure and
lipids with multiple drug combinations
including aspirin, as was the case in the
STENO-2 study, one could argue that it
may be beneﬁcial to shift diabetes man-
agement to control of major cardiovascu-
lar risk factors, e.g., hypertension,
dyslipidemia, and increased procoagula-
toryactivity.However,despiteintensiﬁed
treatment of blood pressure and dyslipi-
demia in STENO-2 in patients at the age
of54.9yearsatentry,30%diedafter13.3
years when they averaged 66 years of age
(11). This mortality rate of 2% per year
is comparable with the mortality rate of
diabetic patients in the observational
study of Juutilainen et al. (4) and is about
fourfold higher than the rate of nondia-
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tensiﬁed-treated patients of the STENO-2
study die so early?
We agree with the conclusion of the
authors that “early and meticulous imple-
mentationofcurrenttreatmentguidelines
remains a major challenge,” particularly
with respect to hyperglycemia.
IMPORTANCE OF THE
GLUCOTRIAD AS A RISK
FACTOR FOR DIABETES
AND VASCULAR DISEASE—A s
shown in numerous prospective studies,
the deleterious effects of dysglycemia—
fasting and postprandial hyperglycemia—
develop before diabetes is diagnosed. In
the Glucose Abnormalities in Patients
with Myocardial Infarction (GAMI) study
of patients with acute coronary syn-
drome, abnormal glucose tolerance was
the strongest independent predictor of
subsequent cardiovascular complications
anddeath(12).IntheAsianPaciﬁcStudy,
fasting plasma glucose was shown to be
an independent predictor of cardiovascu-
lar events up to a level of 5.2 mmol/l
(13). The authors calculated that a differ-
ence of 1 mmol/l in fasting plasma glucose
may be related to reduction of cardiovascu-
lardiseaseby23%.Theimportanceofpost-
prandial hyperglycemia is supported by
richevidencefromprospectivestudies(14).
It was extrapolated from the Diabetes
Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Europe (DECODE)
study that a reduction of 2-h postchal-
lenge hyperglycemia by 2 mmol/l may be
associated with a decrease in all-cause
mortality by 28.8% (15). Based on the re-
sults of epidemiological reports, a near to
normal control of fasting, as well as post-
prandial hyperglycemia, should be
achieved,sinceriskofvasculardiseasestarts
before diabetes is diagnosed (13,16–18). A
freshlookatoldfacts—importanceofpeaks
and valleys, or in scientiﬁc terms, of quality
of glucohomeostasis—was possible when
reliable and precise continuous glucose
measurement systems became available
for clinical use. As shown by Monnier et
al. (19), glucose ﬂuctuations measured as
mean average glycemic excursions were
closely associated with oxidative stress
generation, whereas average glycemic
level was not. Today we have consistent
data from pathophysiological investiga-
tions that glucose ﬂuctuations may be a
vascular risk factor in its own right (Fig.
1). Glucose ﬂuctuations and hyperglyce-
mia are triggers for inﬂammatory re-
sponses via increased mitochondrial
superoxide production (20) and endo-
plasmic reticulum stress (21). Inﬂamma-
tion leads to insulin resistance (22) and
-cell dysfunction, which further aggra-
vateshyperglycemia.Themolecularpath-
ways that integrate hyperglycemia,
oxidative stress, and diabetic vascular
complications have been most clearly de-
scribed in the pathogenesis of endothelial
dysfunction (23). According to the re-
sponse to injury hypothesis, endothelial
dysfunction represents the ﬁrst step of
atherogenesis (24).
The results of these molecular inves-
tigationswereconﬁrmedbystudiesinpa-
tients. Acute hyperglycemia rapidly
attenuated endothelium-dependent vaso-
dilation (25,26) and reduced myocardial
perfusion (27). Thus, direct effects of glu-
cotoxicity, oxidative stress and low grade
inﬂammation act in a vicious circle that
impairs insulin sensitivity, accelerates
and escalates loss of -cells, impairs en-
dothelial function and leads to microvas-
cular and macrovascular disease (Fig. 2).
The best way to prevent chronic progres-
sion of type 2 diabetes is to keep the glu-
cotriad in a normal range as shown in
primary prevention trials with lifestyle
(28,29) or drug intervention (28,30,31),
respectively.
Why is early and meticulous
treatment of hyperglycemia so
important?
As previously discussed, endothelial dys-
function and the risk of vascular disease
develops along a continuum starting at a
level of fasting hyperglycemia below 5.6
mmol/l and of postmeal glucose below
7.8 mmol/l. For ﬂuctuations, we have no
data from prospective studies related to
MAGE or standard deviation. There are,
however, hints that indicate that valleys
with glucose levels below 2.2 mmol/l are
associated with an increased risk of car-
diovascular mortality (32). Possible
harmful effects of strict control of hyper-
Figure 1—Glucotriad.
Figure 2—Harmful effects of hyperglycemia on -cell and endothelial function. AT1R, angioten-
sinIItype1receptor;ICAM-1,intercellularadhesionmolecule1;MCP-1,monocytechemoattrac-
tant protein 1; NEFA, nonesteriﬁed fatty acids; ROS, reactive oxygen species.
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of diabetes and time of intervention.
Thus, there may be a distinct improve-
ment if hyperglycemia is controlled in the
stage of pre-diabetes, or early diabetes
whenA1Cisstillbelow8or7%,asshown
in A Diabetes Outcome Progression Trial
(ADOPT) and the UKPDS (31). In the




control was achieved with a signiﬁcantly
lower incidence of diabetes-related compli-
cations, as was the case in the Kumamoto
(33) and DCCT studies (5). Even more im-
portant, intensive glucose control in those
withnewlydiagnosedtype2diabetesinthe
Diabetes Intervention Study (DIS) (34) and
a post-trial legacy analysis of the UKPDS
(35) was associated with signiﬁcantly lower
all-cause mortality. Conversely, aggressive
treatment of long-term diabetes is associ-
ated with weight gain and high risk of hy-
poglycemia and may be associated with
excessive mortality as indicated by the
ACCORD study (9).
CONCLUSIONS — Recent evidence
from pathophysiology, extensive clinical
experience, and a number of well-
controlled prospective studies clearly
provethathyperglycemiaisakeyriskfac-
torfordiabetes-relatedcomplicationsand
a driving force for deterioration of -cell
function and cardiovascular disease re-
sulting in a signiﬁcant reduction of life
expectancy. Therefore, early intervention
to keep the glucotriad and A1C in a near-
normal range should remain a high prior-
ity to protect our patients, together with
integrated treatment of comorbidities,
such as hypertension, dyslipidemia, and
hypercoagulation. Shifting to a better
form of individualized disease manage-
ment does not imply that diabetologists
should not maintain conﬁdence in their
well-established treatment strategies
based on sound evidence and good clini-
cal practice.
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